natgillin/translations-raw huggingface dataset:
The pharmaceutical formulation according to claim 1, wherein, upon dispersion in the aqueous vehicle, the concentration of melatonin is comprised between 1.0 and 20 mg/ml. 
Farmaceutska formulacija prema patentnom zahtjevu 1, naznačeno time da je koncentracija melatonina nakon disperzije u vodeni vezikul između 1.0 i 20 mg/ml.
Brief Description of the Invention In one embodiment, this invention provides a compound of formula I where at least one of W and Z is N; 
R2 naznačen time, da najmanje jedan od W 1 Z jeste N; pri čemu ostatak dolje je jedna od skupina A ili B
The feed stock of claim 1, wherein the sorbent is selected from the group consisting of trisodium hydrogendicarbonate dehydrate (Trona), sodium bicarbonate, sodium carbonate, zinc ferrite, zinc copper ferrite, zinc titanate, copper ferrite aluminate, copper aluminate, copper manganese oxide, nickel supported on alumina, zinc oxide, iron oxide, copper, copper (I) oxide, copper (II) oxide, limestone, lime, Fe, FeO, Fe2O3, Fe3O4, iron filings, CaCO3, Ca(OH)2, CaCO3, MgO, silica, alumina, china clay, kaolinite, bauxite, emathlite, attapulgite, calcium magnesium acetate, coal ash, egg shells, and Ca-montmorillonite. 
Modificirano zamjensko gorivo u skladu s bilo kojim patentnim zahtjevom 3 do 6, naznačeno time, da sirovina ima omjer O / € od 0,01 do 1,0. Postupak u skladu s patentnim zahtjevom 1 ili 2, ili modificirano zamjensko gorivo u skladu s bilo kojim patentnim zahtjevom 3 do 7, naznačeno time, da su dva ili više sorbensa odabrana iz skupine koju čine: trinatrij hidrogendikarbonat dihidrat (Trona), natrijev bikarbonat, natrijev karbonat, cinkov ferit, cink-bakar ferit, cinkov titanat, bakar-ferit aluminat, bakrov aluminat, bakar-oksid mangan, nikal na glini, cinkov oksid, željezni
Method and system for construction of a building 
METODA I SUSTAV GRAĐENJA ZGRADE
The topical cosmetic formulation according to any one of the preceding claims, further comprising a supplement for LGR6+ stem cells, wherein the supplement comprises at least one of human serum albumin, recombinant albumin, bovine serum albumin, egg albumin, plant hydrolysate, beta-cyclodextrin, glutamine, phospholipids, fibronectin, hyaluronate, hyaluronic acid, epidermal growth factor, fibroblast growth factor, plant hydrolysate, L-alanyl-Lglutamine, gelatin, recombinant gelatin, vitamin E, Tocopheryl Nicotinate, Coenzyme Q10, and ubiquinone. 
Topikalna kozmetička formulacija u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što dodatno sadrži dodatni sastojak za matične stanice LGR6+, gdje dodatni sastojak uključuje najmanje jedno od ljudskog serumskog albumina, rekombinantnog albumina, goveđeg serumskog albumina, albumina iz jaja, biljnog hidrolizata, B-ciklodekstrina, glutamina, fosfolipida, fibronektina, hijualuronata, hijualuronske kiseline, epidermalnog čimbenika rasta, čimbenika rasta fibroblasta, biljnog hidrolizata, l-alanil-l-glutamina, želatine, rekombinantne želatine, vitamina E, tokoferil-nikotinata, koenzima Q10, te ubikinona.
iii) said reaction is performed for a time period of no more than 1.5 h, such as no more than 1 h, such as no more than 0.75 h, such as around 0.5 h, and 
iii) spomenuta reakcija se izvodi tokom vremenskog peroida najduže do 1,5 sata, kao što je najduže do 1 sata, kao što je najduže do 0,75 sata, kao što je oko 0,5 sata, i
A pharmaceutical composition for use in the treatment of neuropathic pain and/or neuropathic pain syndromes comprising a compound as defined in any of claims 1 to 3 in free form or in the form of a pharmaceutically acceptable salt, together with pharmaceutically acceptable diluents or carriers, and whereby the neuropathic pain is a neuropathic pain and/or neuropathic pain syndrome as defined in any of claims 4 to 8. 
Farmaceutski pripravak za upotrebu za liječenje neuropatske boli i/ili sindroma neuropatske boli naznačen time da sadrži spoj definiran u bilo kojem od zahtjeva 1 do 3 u slobodnom obliku ili u obliku farmaceutski prihvatljive soli, zajedno s farmaceutski prihvatljivim razrjeđivačima ili nosačima, i pri čemu neuropatska bol je neuropatska bol i/ili sindrom neuropatske boli kao što je definirano u bilo kojem od zahtjeva 4 do 8.
The vaccine of the present invention is a combination of at least 2, preferably at least 3, more preferably at least 4, even more preferably at least 5, peptides derived from amino acid residues 150 to 170 and/or 205 to 225 of PCSK9 (SEQ ID No. 9). 
HR P20160392 T1 PATENTNI ZAHTJEVI Cjepivo, naznačeno time, da obuhvaća najmanje dva fragmenta proproteinske konvertaze subtilizin/keksin tipa 9 (PCSK9), pri čemu barem jedan od navedena najmanje dva fragmenta sadrže najmanje osam uzastopnih aminokiselinskih ostataka od aminokiselinskih ostataka 150 do 170 od PCSK9 u skladu sa
The antibody drug conjugate of claim 1, wherein the anti-DLL3 monoclonal antibody comprises a light chain variable region comprising an amino acid sequence set forth as SEQ ID NO: 212 and a heavy chain variable region comprising an amino acid sequence set forth as SEQ ID NO: 213. 
Konjugat protutijelo-lijek prema bilo kojem od zahtjeva 1 do 5, naznačen time, da protutijelo anti-DLL3 obuhvaća varijabilno područje slabog lanca koje obuhvaća aminokiselinsku sekvencu prema SEQ ID NO:210 1 varijabilno područje jakog lanca koje obuhvaća aminokiselinsku sekvencu prema SEQ ID NO:211.
The aqueous pharmaceutical suspension according to claim 7, the ratio of the amount of (sucrose or invert sucrose): (xylitol; sorbitol or sorbitol solution, or maltitol solution) is about 1:1. 
Vodena farmaceutska suspenzija u skladu s patentnim zahtjevom 7, naznačena time što odnos količina (saharoza ili invertna saharoza)/(ksilitol, sorbitol ili otopina sorbitola ili otopina maltitola) je otprilike 1:1.
a cytotoxic agent, optionally a chemotherapeutic agent, a drug moiety, an antibiotic, a radioactive isotope, and a nucleolytic enzyme; 
citotoksično sredstvo, opcijski kemoterapeutsko sredstvo, dio molekule lijeka, antibiotik, radioaktivni izotop i nukleolitički enzim;
A pharmaceutical composition in accordance with claim 9, wherein the pharmaceutical composition is substantially free of propylene glycol. 
Farmaceutski sastav prema zahtjevu 9, naznačen time, da je taj farmaceutski sastav uglavnom bez propilenglikola.
The silencer unit as defined in claim 1 or 2, wherein the air inlets and air outlets of the HRV unit are located on one side, preferably the upper side, of the HRV unit substantially in a planar arrangement within a plane defined by said one side of the HRV unit, said planar arrangement of air inlets and air outlets being rotationally asymmetric with respect to rotation of said arrangement around an axis of rotation normal to said plane, and wherein the silencer ducts (2, 4, 6, 8) of the silencer unit (1) have duct ends (2a, 4a, 6a, 8a) arranged in a substantially planar arrangement corresponding to the planar arrangement of the air inlets and air outlets of the HRV unit. 
Jedinica prigušivača definirana kao prema zahtjevu 1 ili 2, naznačeno time da su ulazi i izlazi zraka HRV jedinice pozicionirani na jednoj strani, poželjno na gornjoj strani, jedinice HRV znatno u planarnom rasporedu unutar površine definirane spomenutom jednom stranom jedinice HRV, spomenuti planarni raspored ulaza i izlaza zraka koji je rotacijski asimetričan u odnosu na rotaciju spomenutog rasporeda oko normalne osi rotacije na spomenutu površinu, te naznačeno time da kanali prigušivača (2, 4, 6, 8) jedinice prigušivača (1) imaju završetke kanala (2a, 4a, 6a, 8a) raspoređene u znatno planarnom rasporedu koji odgovara planarnom rasporedu ulaza i izlaza zraka jedinice HRV.
means (301-1) for outer coding the L1 signaling data by a Bose-Chadhuri-Hocquenghem, BCH, coding scheme and means (303-1) for inner coding the outer encoded L1 signaling data by a Low Density Parity Check, LDPC, coding scheme; 
Uređaj iz patentnog zahtjeva 4, pri čemu uređaj nadalje obuhvaća: sredstvo (301) za vanjsko kodiranje PLP podataka pomoću sheme kodiranja Bose-Chadhuri-Hocquenghem, BHC; i sredstvo (303) za unutarnje kodiranje vanjsko kodiranih PLP podataka shemom kodiranja provjere pariteta niske gustoće (LDPC).
The test compounds are initially assayed at 1 and 0.1 µM and then at a range of concentrations chosen such that the middle dose would cause about 50% inhibition of a Radio-RUP25 Ligand binding (i.e., IC50). 
Ispitivani spojevi su prvo ispitani pri 1 i 0.1 uM i zatim u rasponu koncentracija izabranim tako da srednja doza uzrokuje oko 50% inhibicije vezivanja Radiološki označenog RUP25 liganda (tj. ICsQ).
In this manner, the idler gear 88 can be moved generally closer to or further away from the drive and driven gears 84,86. 
Na ovaj način, potporni zupčanik (88) može biti pomaknut bliže ili dalje od pogonskog i pogonjenog zupčanika (84), (86).
injecting the selected cell into a developing non-human embryo; or cultivating the resulting cell in an appropriate medium and transferring into the resultant cell into a synchronised recipient for generating a transgenic non-human animal. 
I. Injektirane odabrane stanice u razvoj ne-ljudskog embrija; ili II. kultiviranje rezultirajuće stanice u odgovarajućem mediju i prenošenje u nastalu stanicu u sinkronizirani primatelj za generiranje transgenične ne-humane životinje.
The FTI for use of any one of claims 1 to 3, wherein said H-Ras mutation comprises at least one amino acid substitution at a codon selected from the group consisting of G12, G13 and Q61. 
Spoj za uporabu u skladu s patentnim zahtjevom 1, pri čemu H-Ras mutacija navedenog subjekta sadrži nadomjestak amino kiseline u kodonu izabranom iz grupe koja sadrži G12, G13 1 QGI.
a light chain variable domain comprising the amino acid sequence of SEQ ID NO:11, wherein CDR1 is defined by SEQ ID NO:16, CDR2 is defined by SEQ ID NO:24, and CDR3 is defined by SEQ ID NO: 19; and a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:12, wherein CDR1 is defined by SEQ ID NO:25, CDR2 is defined by SEQ ID NO:14, and CDR3 is defined by SEQ ID NO:20, wherein regions of the light chain variable domain and heavy chain variable domain outside the CDR regions are framework regions, and wherein at least one framework region comprises none, one, two or three amino acid substitutions. 
varijabilnu domenu lakog lanca, koja sadrži aminokiselinski slijed SEQ ID NO:11, gdje je CDR1 definiran sa SEQ ID NO:16, CDR2 je definiran sa SEQ ID NO:24, a CDR3 je definiran sa SEQ ID NO:19; i varijabilnu domenu teškog lanca, koja sadrži aminokiselinski slijed SEQ ID NO:12, gdje je CDR1 definiran sa SEQ ID NO:25, CDR2 je definiran sa SEQ ID NO:14, a CDR3 je definiran sa SEQ ID NO:20, gdje su područja varijabilne domene lakog lanca i varijabilne domene teškog lanca izvan CDR područja osnovna, te gdje najmanje jedno osnovno područje ne sadrži niti jednu, ili sadrži jednu, dvije ili tri aminokiselinske zamjene.
In one preferred variant of the invention, the pharmaceutical composition for topical application is in the form of a solution, a gel or an emulsion. 
Spoj prema jednom od zahtjeva 1 do 8, naznačen time što se nalazi u farmaceutskom pripravku za topikalnu primjenu.
The invention relates to a process for the preparation of a compound of formula (I): or a tautomer, stereoisomer, or a pharmacologically acceptable salt of any of the foregoing, wherein: 
HR P20140655 T1 PATENTNI ZAHTJEVI Postupak za pripremu spoja čija je formula (I): ili tautomera, stereoizomera ili neke farmakološki prihvatljive soli bilo kojeg od prije navedenih gdje je
Vector comprising a nucleotide sequence encoding a polypeptide consisting of the extra-cellular IPT-3 and IPT-4 domains of hepatocyte growth factor receptor for use as a medicament for treating cancer. 
Vektor koji sadrži sekvencu nukleotida koja kodira polipeptid koji sadrži vanstanične IPT-3 i IPT-4 domene receptora faktora rasta hepatocita za uporabu kao lijek za liječenje raka. HR P20110643 T1
supplying the liquid plastic material via the supply (5) and the channels for soaking and thereby filling up the reinforcement package with the plastic material; 
- < dovođenje tekućeg plastičnog materijala kroz dovod (5) i kanale za kvašenje i time punjenje tijela za ojačanje s plastičnim materijalom;
acryl amide or acrylic esters such as methylmethacrylate, or mixtures thereof; alkali polyphosphates; or mixtures thereof. 
akril amid ili akrilni esteri kao što je metilmetakrilat, ili njihove mješavine; alkalni polifosfati; ili njihove mješavine, te pri čemu
The present application is a national stage filing of International patent application Serial No. 
Broj europske prijave patenta: EP 13739708.9 Datum podnošenja europske prijave patenta:
The reaction mixture may further contain carbon tetrachloride, for example in an amount up to 50 wt% of the reaction mixture, for example from 3 to 30 wt%. 
Postupak iz patentnog zahtjeva 1, pri čemu reakcijska smjesa nadalje obuhvaća ugljikov tetraklorid. Postupak iz patentnog zahtjeva 2, pri čemu je ugljikov tetraklorid prisutan u količini do 50 težinskih postotnih udjela reakcijske smjese.
A product or kit comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, as defined in claim 1, or a pharmaceutical compositions comprising a therapeutically effective amount of a compound accordinq to claim 1 or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient, carrier or diluent, and one or more chemotherapeutic agents, as a combined preparation for simultaneous, separate or sequential use in anticancer therapy. 
Proizvod ili komplet, naznačen time što sadrži spoj formule (I), ili njegovu farmaceutski prihvatljivu sol, u skladu s patentnim zahtjevom 1, ili njegove farmaceutske pripravke u skladu s patentnim zahtjevom 11 i jedno ili više kemoterapijskih sredstava, kao kombinirani pripravak za istodobnu, odvojenu ili uzastopnu upotrebu u antikanceroznoj terapiji.
A compound represented by the following formula [I'] or a pharmaceutically acceptable salt thereof: wherein R1', R2' and R6 are the same or different and each is a C1-6 alkyl group, a C2-6 alkynyl group, wherein the C1-6 alkyl group and the C2-6 alkenyl group are optionally substituted by 1 to 3 substituents selected from group A of claim 1, or m is an integer of 0 or 1 to 4, ring Cy is a C3-12 carbon ring group or a heterocyclic group wherein the heterocyclic group is a saturated or unsaturated ring having, besides carbon atom, 1 to 4 hetero atoms selected from an oxygen atom, a nitrogen atom and a sulfur atom, and the C3-12 carbon ring group and the heterocyclic group are optionally substituted by 1 to 5 substituents selected from group B of claim 1, provided that, when the moiety is then R2' is not a methyl group, and when R2' is a phenyl group, then R1' is not a phenyl group, and other symbols are as defined in claim 1. 
C24 alkinilna skupina, gdje su Cig alkilna skupina i C24 alkenilna skupina izborno supstituirane s 1 do 3 supstituenta, koje se bira iz skupine A u skladu s patentnim zahtjevom 1, ili m je cijeli broj od 0 ili 1 do 4, prsten Cy je prstenasta skupina s C3_12 ugljika ili heterociklička skupina gdje heterociklička skupina je zasićen ili nezasićen prsten, koja uz atom ugljika sadrži i 1 do 4 heteroatoma, koje se bira između atoma kisika, atoma dušika i atoma sumpora, gdje su prstenasta skupina s C3.;> ugljika i heterociklička skupina izborno supstituirane s 1 do 5 supstituenta, koje se bira iz skupine B u skladu s patentnim zahtjevom 1, uz uvjet da kada ostatak BO keeo X
is selected from the group consisting of B-Ala, 4-AMB, 5-aminovaleryl, and 4-AMPA; is Arg; is selected from the group consisting of Asp and Glu; 
se bira iz skupine koju čine Ala, 5-aminovaleril, Asp, Glu, Gly, Phe, dPhe, te sukcinil; se bira iz skupine koju čine Arg, Lys(iPr), te Lys(Me2);
inlet side of the steam-producing thermoblock 
. izlazna strana termobloka 4
The process of claim 11, wherein the hydrogenation is carried out at a temperature of about 20°C. 
Postupak prema zahtjevu 1, gdje se hidrogenacija provodi pomoću katalizatora i donora vodika.
The apparatus of claim 1 wherein the mixture comprises relatively small amounts of biologically active or chemical substance metered into a relatively high volume of pressurized air. 
Sustav prema zahtjevu 1, naznačen time što mješavina obuhvaća relativno male količine biološki aktivne ili kemijske supstance dozirane u relativno veliki volumen zraka pod tlakom.
Subsequently the container can be opened by the piercer piercing the seal on the outlet of the container by forcing the container downwards overcoming the resilience of the resilient support means. 
Nakon toga se spremnik može otvoriti bušenjem čepa na izlazu spremnika s bušilom tako, da se spremnik prisili da ide prema dolje i da nadvlada elastičnost elastičnog nosećeg elementa.
The crude product was purified by flash chromatography on silica using gradient elution (heptane/ethyl acetate). 
Čvrsti produkt se pročišćava sa brzom kromatografijom na silika gelu uz korištenje gradijenta ispiranja (heptan/etil acetat).
Amount of the polypeptide mixture of the invention dissolved 
Datum podnošenja europske prijave patenta:
at least one phosphate salt. 
(ID i b) najmanje jednu fosfatnu sol.
wherein R4 is H or —C1-C4 alkyl, —C0-C2 alkyl and —C1-C6 alkyl may be unsubstituted or substituted with 1 or 2 —CH3 groups and/or 1 to 3 —F groups, and 
C0-C2 alkil i -C1-C6 alkil može biti nesupstituiran ili supstituiran s 1 ili 2 skupine -CH3 i/ili 1 do 3 skupine -F, i Ar i Het je svaki neovisno kako je definirano u formuli I do formule III.
The compound of claim 1, wherein R1-R2 is selected from the group consisting of: 
HR P20190096 T1 Spoj sukladno patentnom zahtjevu 1, naznačeno time R1-R2 da je H
A represents a structure represented by the following formula [2]: wherein 
A-Y pri čemu A predstavlja strukturu predstavljenu sljedećom formulom [2]:
4.9 g of water wet white solid (Rf of HPLC identical to reference) is obtained, which is used in the deprotection reaction without further purification. 
Dobiva se 4.9 g bijele krutine vlažne od vode (Rf od HPLC identičan referenci), koja se koristi u reakciji deprotekcije bez daljnjeg pročišćavanja.
A method of inhibiting the replication of hepatitis C virus, the method comprising supplying a hepatitis C viral NS3 protease inhibitory amount of the pharmaceutical composition of claim 16. 
Inhibirajuća količina farmaceutskog pripravka NS3 proteaze virusa hepatitisa C u skladu s patentnim zahtjevom 10, naznačen time, da je za inhibiciju replikacije virusa hepatitisa C.
In a further aspect the present invention provides an antibody comprising a polypeptide of SEQ ID NO:1 and a polypeptide of SEQ ID NO:2, or 
Monoklonalno protutijelo specifično za humani IL-4, naznačeno time, da obuhvaća polipeptid od SEQ ID NO:1i polipeptid od SEQ ID NO:2.
The dental post according to at least one of the claims 1 to 2, characterized in that X-ray absorbing material is embedded in said post. 
Zubni most u skladu s najmanje jednim od patentnih zahtjeva 1 do 2, naznačen time što je u navedeni most uklopljen materijal koji apsorbira rendgensko zračenje.
The use of claim 20 or 21, wherein the second agent is quinidine, and wherein the dosage amount of the compound of Formula I or pharmaceutically acceptable salt thereof is 10-60 mg, and the dosage amount of quinidine is 2.5-30 mg. 
Uporaba u skladu s patentnim zahtjevom 20 ili 21, pri čemu je drugi terapijski agens kinidin, i pri čemu je količina doziranja tvari formule I ili njene farmaceutski prihvatljive soli 10-60 mg, a količina doziranja kinidina je 2.5-30 mg.
is phenyl or HET(1), wherein A2 is substituted with 1-3 substituent groups which are each independently CH3, CF3, -OCH3, -OCF3, halogen, -CN, -OH, or C3-4cycloalkyl optionally substituted with 1-3 substituents which are each independently halogen, CF3, CH3, -OCF3, or -OCH3; and a is 0, 1, or 2. 
je fenil ili HET(1), pri čemu je A2 supstituiran sa 1-3 grupe supstituenata, od kojih je svaka nezavisno CH3, CF3, -OCH3, -OCF3, halogen, -CN, -OH ili C3-4cikloalkil, po izboru supstituiran sa 1-3 supstituenta, od kojih je svaki nezavisno, halogen, CF3, CH3, -OCF3 ili -OCH3; i a je 0, 1 ili 2.
Preferably each hole of the plurality of holes at the second end of the housing extends through an outer surface of the housing, the outer surface opposing the opening at the first end of the housing. There is also disclosed herein an apparatus comprising or including 
Uređaj u skladu s patentnim zahtjevom 1, naznačen time, da je vanjski opseg prvog kraja (A) kućišta (12) manji po duljini od vanjskog opsega drugog kraja (B) kućišta (12).
the securing system (3) having at least two connecting elements (11) for strands (8) or rods of the first reinforcement layer (16), 
- < gdje sigurnosni aranžman (3) ima najmanje dva spojna elementa (11) za užad (8) ili šipke prvog ojačavajućeg sloja (16),
a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to a polynucleotide sequence encoding the heavy chain variable domain sequence of H5; 
slijed aminokiselina kodiran polinukleotidnim slijedom koji je najmanje 80% identičan slijedu SEQ ID NO:360; iii.
A lighting module of claim 4 further including a microchip configured to regulate energy flowing to said light emitting diode, wherein output of said amplifying circuit is input to said microchip. 
Rasvjetni modul iz patentnog zahtjeva 19, naznačen time, da dodatno sadržava mikročip koji je konfiguriran tako da regulira tok energije do navedene LED diode, pri čemu je navedeni izlaz navedenog pojačivačkog sklopa ulaz navedenom mikročipu.
The antibody of claim 1, which is not capable of detectably binding to CLDN4 associated with the surface of a cell that expresses CLDN4 and/or is not capable of detectably binding to CLDN3 associated with the surface of a cell that expresses CLDN3, wherein binding of the antibody to CLDN4 and CLDN3 is determined by flow cytometry analysis as binding of the antibody to CLDN4 and CLDN3 expressed on the surface of intact cells. 
Antitijelo prema patentnom zahtjevu 1, koje nije sposobno da se detektabilno veže za CLDN4 povezan s površinom stanice koja eksprimira CLDNA i/ili nije sposobno da se detektabilno veže za CLDN3 povezan s površinom stanice koja eksprimira CLDN3, pri čemu je vezanje antitijela za CLDN4 i CLDN3 određeno pomoću protočno citometrijske analize kao vezanje antitijela za CLDN4 i CLDN3 eksprimiranih na površini intaktnih stanica.
The compound of claim 1 selected from the group consisting of: 
Postupak u skladu s patentnim zahtjevom 12, naznačen time što Spoj 3 se dobiva postupkom kojeg se bira iz skupine koju čine:
An isolated antigen-binding region according to claim 2, which comprises a heavy chain or light chain amino acid sequence selected from the group consisting of the 
Protutijelo prema zahtjevu 1, naznačeno time da sadrži varijabilnu sekvencu amino kiseline lakog lanca od MF-T VL iz Tablice 4.
The method of claim 2, wherein the polypeptide is fused to a heterologous peptide selected from any of human serum albumin (HSA), immunoglobulin heavy chain constant region (Fc), polyhistidine, glutathione S transferase (GST), thioredoxin, protein A, protein G, or maltose binding protein (MBP), or a fragment thereof, wherein the heterologous peptide is fused at either the amino-terminal end or the carboxy-terminal end of the polypeptide. 
Polipeptid prema bilo kojem od zahtjeva 1 do 8, naznačen time, da je polipeptid fuzioniran na bilo koji od sljedećih: ljudski serum albumin (HSA), konstantno područje imunoglobulina jakog lanca (Fc), polihistidin, transferaza glutationa S (GST), tioredoksin, protein A, protein G, ili protein koji veže maltozu (MBP), ili njihov fragment, te je pritom peptid fuzioniran na amino-završni kraj polipeptida ili na karboksi-završni kraj polipeptida.
The invention also provides the use of IL-2 microaggregates of the invention in the manufacture of a medicament, wherein the medicament is for administration to a patient who has been pre-treated with a second pharmaceutical agent. 
Izum također daje uporabu IL-2 mikroagregata iz izuma u proizvodnji medikamenta, kod čega je medikament za davanje pacijentu koji se prethodno liječio drugim farmaceutskim agensom.